Able SL, Johnston JA, Adler LA, Swindle RW (2007) Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med 37(1):97–107
PubMedCrossRefAdler LA, Spencer T, Reimherr F et al (2003) Efficacy and safety of atomoxetine in long-term open label treatment of adults with ADHD. Poster presented during the APA annual meeting, San Francisco
Adler A, Liebowitz M, Kronenberger W et al (2006) Atomoxetin treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety 26:212–221
CrossRefAdler LA, Goodman DW, Kollins SH et al (2008) Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 69(9):1364–1373
PubMedCrossRefAgarwal R, Goldenberg M, Perry R, IsHak WW (2012) The quality of life of adults with attention deficit hyperactivity disorder: a systematic review. Innov Clin Neurosci 9(5–6):10–21
PubMedPubMedCentralAmerican Psychiatric Association (2013) Diagnostics and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). American Psychiatric Association, Arlington
CrossRefAntshel KM, Kaul P, Biederman J et al (2013) Posttraumatic stress disorder in adult attention-deficit/hyperactivity disorder: clinical features and familial transmission. J Clin Psychiatry 74(3):e197–e204
PubMedCrossRefArnold LE, Hodgkins P, Caci H et al (2015a) Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review. PLoS One 25;10(2):e0116407
Arnold LE, Hodgkins P, Kahle J et al (2015b) Long-term outcomes of ADHD: academic achievement and performance. J Atten Disord. E pub (vor Druck)
Asherson P, Gurling H (2012) Quantitative and molecular genetics of ADHD. Curr Top Behav Neurosci 9:239–272
PubMedCrossRefAsherson P, Akehurst R, Kooij JJ et al (2012) Under diagnosis of adult ADHD: cultural influences and societal burden. J Atten Disord 16(5 Suppl):20S–38S
PubMedCrossRefBaer N, Kisch P (2010) Training bei ADS im Erwachsenenalter TADSE. Beltz Verlag, Weinheim
Baird AL, Coogan AN, Siddiqui A et al (2012) Adult attention-deficit hyperactivity disorder is associated with alterations in circadian rhythms at the behavioural, endocrine and molecular levels. Mol Psychiatry 17(10):988–995
PubMedCrossRefBaird AL, Coogan AN, Kaufling J et al (2013) Daily methylphenidate and atomoxetine treatment impacts on clock gene protein expression in the mouse brain. Brain Res 1513:61–71
PubMedCrossRefBanaschewski T, Brandeis D, Heinrich H et al (2003) Association of ADHD and conduct disorder – brain electrical evidence for the existence of a distinct subtype. J Child Psychol Psychiatry 44:356–376
PubMedCrossRefBangs ME, Emslie GJ, Spencer TJ et al (2007) Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 17:407–420
PubMedCrossRefBarkley RA (1997) Behavioural inhibition, sustained attention and executive functions. Constructing a unifying theory of ADHD. Psychol Bull 121:65–94
PubMedCrossRefBarkley RA, Fischer M, Smallish L, Fletcher K (2002a) The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 111(2):279–289
PubMedCrossRefBarkley RA, Murphy KR, Dupaul GI, Bush T (2002b) Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes and the role of executive functioning. J Int Neuropsychol Soc 8:655–672
PubMedCrossRefBarkley RA, Fischer M, Smallish L, Fletcher K (2004) Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry 45(2):195–211
PubMedCrossRefBarkley RA, Fischer M, Smallish L, Fletcher K (2006) Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 45(2):192–202
PubMedCrossRefBartlik B, Harmon G (1997) Use of methylphenidate in a patient with glaucoma and attention deficit disorder: a clinical dilemma. Arch Gen Psychiatry 54:188–189
PubMedCrossRefBenkert O, Hippius H (Hrsg) (2014) Kompendium der Psychiatrischen Pharmakotherapie, 10. Aufl. Springer, Heidelberg
Berquin PC, Giedd JN, Jacobson LK et al (1998) Cerebellum in attention deficit/hyperactivity disorder. Neurology 50:1087–1093
PubMedCrossRefBiederman J, Spencer T (2002) Methylphenidate in treatment of adults with attention deficit/hyperactivity disorder. J Atten Disord 6:101–107
Biederman J, Faraone SV, Spencer T et al (1993) Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 150:1792–1798
PubMedCrossRefBiederman J, Wilens T, Mick E et al (1999) Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 104:e20
PubMedCrossRefBiederman J, Faraone SV, Spencer TJ et al (2006) Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 67(4):524–540
PubMedCrossRefBond DJ, Hadjipavlou G, Lam RW et al (2012) Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry 24(1):23–37
PubMedBreyer JL, Botzet AM, Winters KC et al (2009) Young adult gambling behaviors and their relationship with the persistence of ADHD. J Gambl Stud 25(2):227–238
PubMedPubMedCentralCrossRefBrod M, Johnston J, Able S, Swindle R (2006) Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale (AAQoL): a disease-specific quality-of-life measure. Qual Life Res 15(1):117–129
PubMedCrossRefBrown TE (2001) Brown attention deficit disorder scales (BADDS) for adults (18 yrs and up). In: Brown ADD rating scales for children, adolescents and adults. PsychoCorp/Pearson, San Antonio
Broyd SJ, Demanuele C, Debener S et al (2009) Default-mode brain dysfunction in mental disorders: a systematic review. Neurosci Biobehav Rev 33:279–296
PubMedCrossRefBrus MJ, Solanto MV, Goldberg JF (2014) Adult ADHD vs. bipolar disorder in the DSM-5 era: a challenging differentiation for clinicians. J Psychiatr Pract 20(6):428–437
PubMedCrossRefBush G, Frazier JA, Rauch SL (1999) Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the counting stroop. Biol Psychiatry 45:1542–1552
PubMedCrossRefCaci H, Asherson P, Donfrancesco R et al (2015) Daily life impairments associated with childhood/adolescent attention-deficit/hyperactivity disorder as recalled by adults: results from the European Lifetime Impairment Survey. CNS Spectr 20(2):112–121
PubMedCrossRefCarpentier PJ, de Jong CA, Dijkstra BA et al (2005) A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction 100:1868–1874
PubMedCrossRefCastellanos F, Giedd J, Marsh W et al (2001) Quantitative brain magnetic resonance imaging in girls with attention deficit/hyperactivity disorder. Arch Gen Psychiatry 58:289–295
PubMedCrossRefCastells X, Ramos-Quiroga JA, Rigau D et al (2011) Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 25(2):157–169
PubMedCrossRefCheon KA, Ryu YH, Kim YK et al (2003) Dopamine transporter density in the basal ganglia assessed with (123)IPT SPECT in children with attention deficit hyperactivity disorder. Eur J Nucl Med Mol Imaging 30:306–311
PubMedCrossRefChristiansen H, Hirsch O, Abdel-Hamid M, Kiss B (2014) Deutschsprachige Adaption der Conners’ Adult Rating Scale (CAARS™) von Conners CK, Erhardt D, Sparrow E. Hans Huber Verlag, Bern
Cobos JP, Siñol N, Pérez V, Trujols J (2012) Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction. Br J Clin Pharmacol 77(2):337–356
CrossRefCoghill RD, Caballero B, Sorooshian S, Civil R (2014) A systematic review of the safety of lisdexamfetamine desmetylate. CNS Drugs 28:497–511
PubMedPubMedCentralCrossRefColla M, Heuser I (2005) Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Erwachsenenalter. In: Holsboer F, Gründer, Benkert O (Hrsg) Handbuch der psychiatrischen Pharmakotherapie. Springer, Wien/New York
Conners CK, Eisenberg L (1963) The effects of methylphenidate on symptomatology and learning in disturbed children. Am J Psychiatry 120:458–464
PubMedCrossRefCooper WO, Habel LA, Sox CM et al (2011) ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 365:1896–1904
PubMedPubMedCentralCrossRefCortese S (2012) The neurobiology and genetics of Attention-Deficit/Hyperactivity Disorder (ADHD): what every clinician should know. Eur J Paediatr Neurol 16:422–433
PubMedCrossRefCortese S, Konofal E, Lecendreux M et al (2005) Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature. Sleep 28(8):1007–1013
PubMedCox DJ, Merkel RL, Kovatchev B, Seward R (2000) Effect on stimulant medication on driving performance of young adults with attention deficit hyperactivity disorder: a preliminary double-blind placebo controlled trial. J Nerv Ment Dis 188:230–234
PubMedCrossRefD’Amelio R, Retz W, Philipsen A, Rösler M (2009) Psychoedukation und Coachin ADHS im Erwachsenenalter. Manual zur Leitung von Patienten- und Angehörigengruppen. Elsvier GmbH, München
Dalsgaard S, Kvist AP, Leckman JF et al (2014) Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. J Child Adolesc Psychopharmacol 24:302–310
PubMedPubMedCentralCrossRefDalsgaard S, Leckman JF, Mortensen PB et al (2015) Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry 2(8):702–709
PubMedCrossRefDavids E (2005) Psychostimulanzien und weitere Medikamente zur Behandlung der ADHS und Hypersomnien. In: Benkert O, Hippius EJ (Hrsg) Kompendium der psychiatrischen Pharmakotherapie, 5. Aufl. Springer, Berlin/Heidelberg/New York/Tokio
de Graaf R, Kessler RC, Fayyad J et al (2008) The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med 65(12):835–842
PubMedPubMedCentralCrossRefDe Luca V, Muglia P, Vincent JB et al (2004) Adrenergic alpha 2C receptor genomic organization: association study in adult ADHD. Am J Med Genet B Neuropsychiatr Genet 127B:65–67
PubMedCrossRefDickstein SG, Bannon K, Castellanos FX et al (2006) The neural correlates of attention deficit hyperactivity disorder: an ALE meta-analysis. J Child Psychol Psychiatry 47:1051–1062
PubMedCrossRefDilling H, Mombour W, Schmidt MH (Hrsg) (1991) Internationale Klassifikation psychischer Störungen. ICD-10, Kapitel V (F). Klinische diagnostische Leitlinien, 2. Aufl. Huber, Bern
Ding YS, Fowler JS, Volkow ND et al (1997) Chiral drugs: comparison of the pharmacocinetics of [11C] d-threo and
l-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl) 131:71
CrossRefDorrego MF, Canevaro L, Kuzis G et al (2002) A randomized, double-blind, cross-over study of methylphenidtae and lithium in adults with attention deficit hyperactivity disorder. J Neuropsychiatry Clin Neurosci 14:289–293
PubMedCrossRefDougherty DD, Bonab AA, Spencer TJ et al (1999) Dopamine transporter density is elevated in patients with ADHD. Lancet 354:2132–2133
PubMedCrossRefDresel S, Krause J, Krause KH et al (2000) Attention deficit hyperactivity disorder: binding of [99mTc] TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 27:1518–1524
PubMedCrossRefEakin L, Minde K, Hechtman L et al (2004) The martial and family functioning of adults with ADHD and their spouses. J Atten Disord 8:1–10
PubMedCrossRefEbert D, Krause J, Roth-Sackenheim C (2003) ADHS im Erwachsenenalter – Leitlinien auf der Basis eines Expertenkonsensus mit Unterstützung der DGPPN. Nervenarzt 10:939–946
Ernst M, Kimes AS, London ED et al (2003) Neural substrates of decision making in adults with attention-deficit/hyperactivity disorder. Am J Psychiatry 53:871–8788
Fachinformation Attentin. Medice Iserlohn
Fachinformation Medikinet adult. Medice Iserlohn
Fachinformation Ritalin adult. Novartis, Nürnberg
Falkai P, Wittchen HU et al (Hrsg) (2015) Diagnostische Kriterien DSM-5: Deutsche Ausgabe. American Psychiatric Association/Hogrefe, Verlag Göttingen
Faraone SV, Wilens T (2003) Does stimulant treatment lead to substance use disorder? J Clin Psychiatry 64:9–13
PubMedFaraone SV, Spencer T, Aleardi M et al (2004) Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit-hyperactivity disorder. J Clin Psychopharmacol 24:24–29
PubMedCrossRefFaraone SV, Biederman J, Mick E (2006) The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 36(2):159–165. Review
PubMedCrossRefFaraone SV, Asherson P, Banaschewski T et al (2015) Attention-deficit/hyperactivity disorder. Nat Rev Dis Prim
Fayyad J, DeGraaf R, Kessler R, Alonos J et al (2007) Cross-national prevalence and correlates of adult attention-deficit hyperactitivity disorder. Br J Psychiatry 190:402–409
PubMedCrossRefFindling RL (1996) Open-label treatment of comorbid depression and attentional disorder with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolesc Psychopharmacol 6(3):165–175
PubMedCrossRefFleck K, Jacob C, Philipsen A et al (2015) Child impact on family functioning: a multivariate analysis in multiplex families with children and mothers both affected by attention-deficit/hyperactivity disorder (ADHD). Atten Defic Hyperact Disord 7(3):211–223
PubMedCrossRefFranke AG, Bonertz CC, Christmann MM et al (2011) Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 2:60–66
CrossRefFranke B, Faraone SV, Asherson P et al (2012) The genetics of attention deficit/hyperactivity disorder in adults, a review. Mol Psychiatry 17:960–987
PubMedCrossRefFredriksen M, Halmoy A, Faraone SV, Haavik J (2013) Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. Eur Neuropsychopharmacol 23:508–527
PubMedCrossRefFriedman LA, Rapoport JL (2015) Brain development in ADHD. Curr Opin Neurobiol 30:106–111
PubMedCrossRefGarrettson LK, Perel JM, Dyton PG (1969) Methylphenidate interaction with both anticonvulsants and ethyl biscoumacetate. JAMA 207:2053–2056
PubMedCrossRefGreiner A, Langer S, Schütz A (2012) Stressbewältigungstraining für Erwachsene mit ADHS. Springer, Heidelberg
CrossRefGuldberg-Kjär T, Sehlin S, Johansson B (2013) ADHD symptoms across the lifespan in a population-based Swedish sample aged 65 to 80. Int Psychogeriatr 25:667–675
PubMedCrossRefHalmøy A, Fasmer OB, Gillberg C, Haavik J (2009) Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment: a cross-sectional study of 414 clinically diagnosed adult ADHD patients. J Atten Disord 13(2):175–187
PubMedCrossRefHeidbreder R (2015) ADHD symptomatology is best conceptualized as a spectrum: a dimensional versus unitary approach to diagnosis. Atten Defic Hyperact Disord 7(4):249–269
Hervey AS, Eppstein JN, Curry JF (2004) Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review. Neuropsychology 18:485–503
PubMedCrossRefHesslinger B, Tebartz van Elst L, Nyberg E et al (2002a) Psychotherapy of attention deficit hyperactivity disorder in adults: a pilot study using a structured skills training program. Eur Arch Psychiatry Clin Neurosci 252:177–184
PubMedCrossRefHesslinger B, Tebartz van Elst L, Thiel T (2002b) Fronto-orbital volume reductions in adult patients with attention-deficit/hyperactivity disorder. Neurosci Lett 328:319–321
PubMedCrossRefHesslinger B, Tebartz van Elst L, Mochan F, Ebert D (2003a) Attention deficit hyperactivity disorder in adults – early vs. late onset in a retrospective study. Psychiatry Res 119:217–223
PubMedCrossRefHesslinger B, Tebartz van Elst L, Mochan F, Ebert D (2003b) A psychological study into the relationship between attention deficit hyperactivity disorder in adult patients and recurrent brief depression. Acta Psychiatr Scand 107:321–322
CrossRefHesslinger B, Philipsen A, Richter H, Ebert D (2004) Psychotherapie der ADHS im Erwachsenenalter. Ein Arbeitsbuch. Hogrefe, Göttingen
Hoogman M, Aarts E, Zwiers M et al (2011) Nitric oxide synthase genotype modulation of impulsivity and ventral striatal activity in adult ADHD patients and healthy comparison subjects. Am J Psychiatry 168:1099–1106
PubMedCrossRefHornig-Rohan M, Amsterdam JD (2002) Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression. Prog Neuropsychopharmacol Biol Psychiatry 26(3):585–589
PubMedCrossRefHumphreys KL, Eng T, Lee SS (2013) Stimulant medication and substance use outcomes: a meta-analysis. JAMA Psychiatry 70(7):740–749
PubMedCrossRefHuss M (2004) Langzeiteffekte der Stimulanzientherapie. In: Schulte-Markwort M, Warnke A (Hrsg) Methylphenidat. Thieme, Stuttgart/New York
Jans T, Philipsen A, Graf E et al (2008) The impact of attention deficit/hyperactivity disorder (ADHD) in mothers on the treatment of their ADHD children – review and summary of the study protocol of a randomized controlled multi-centre trial on parent training. Z Kinder Jugendpsychiatr Psychother 36(5):335–343
PubMedCrossRefJans T, Jacob C, Warnke A et al (2015) Does intensive multimodal treatment for maternal attention deficit hyperactivity disorder (ADHD) improve the efficacy of parent training for children with ADHD? A randomized controlled multicenter trial. J Child Psychol Psychiatr 56(12):1298–313
Jeffers A, Benotsch EG, Koester S (2013) Misuse of prescription stimulants for weight loss, psychosocial variables, and eating disordered behaviors. Appetite 65:8–13
PubMedCrossRefKelly AM, Margulies DS, Castellanos FX (2007) Recent advantages in structured and functional brain imaging studies of ADHD. Curr Psychiatry Rep 9:401–407
PubMedCrossRefKessler RC, Adler L, Ames M et al (2005a) The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med 35:245–256
PubMedCrossRefKessler RC, Chiu WT, Demler O, Walters E (2005b) Prevalence, severity and comorbidity of 12-Month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617–627
PubMedPubMedCentralCrossRefKessler RC, Adler L, Barkley R et al (2006) The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163:716–723
PubMedPubMedCentralCrossRefKirov R, Brand S (2014) Sleep problems and their effect in ADHD. Expert Rev Neurother 14:287–299
PubMedCrossRefKissling C, Retz W, Wiemann S et al (2008) A polymorphism at the 3′-untranslated region of the CLOCK gene is associated with adult attention-deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 147:333–338
PubMedCrossRefKlassen LJ, Bilkey TS, Katzman M et al (2012) Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations. Curr Drug Abuse Rev 5(3):190–198
Knouse LE, Safren SA (2010) Current status of cognitive behavioral therapy for adult attention-deficit hyperactivity disorder. Psychiatr Clin North Am 33(3):497–509
PubMedPubMedCentralCrossRefKoesters M, Becker T, Kilian R et al (2009) Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 23:733–744
PubMedCrossRefKollins SH, MacDonald EK, Rush CR (2001) Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 68:611–662
PubMedCrossRefKonofal E, Lecendreux M, Cortese S (2010) Sleep and ADHD. Sleep Med 11(7):652–658
PubMedCrossRefKooij JJS (2010) Diagnostic Interview for ADHD in adults 2.0 (DIVA 2.0). In: Kooij JJS (Hrsg) Adult ADHD. Diagnostic assessment and treatment, 3. Aufl. Springer (deutsche Übersetzung: Sobanski E, Retz W, Thome J 2012 DIVA Foundation)
Kooij JJ, Bijlenga D (2013) The circadian rhythm in adult attention-deficit/hyperactivity disorder: current state of affairs. Expert Rev Neurother 13:107–116
CrossRefKooij JJ, Middelkoop HA, van Gils K, Buitelaar JK (2001) The effect of stimulants on nocturnal motor activity and sleep quality in adults with ADHD: an open-label case–control study. J Clin Psychiatry 62(12):952–956
PubMedCrossRefKooij SJ, Bejerot S, Blackwell A et al (2010) European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry 10:67
PubMedPubMedCentralCrossRefKooij JJ, Huss M, Asherson P et al (2012) Distinguishing comorbidity and successful management of adult ADHD. J Atten Disord 16(5 Suppl):3S–19S
PubMedCrossRefKotsopoulos N, Connolly MP, Sobanski E, Postma MJ (2013) The fiscal consequences of ADHD in Germany: a quantitative analysis based on differences in educational attainment and lifetime earnings. J Ment Health Policy Econ 16(1):27–33
PubMedKrause J, Krause KH (2013) ADHS im Erwachsenenalter: Symptome, Differenzialdiagnose, Therapie, 4. Aufl. Schattauer, Stuttgart/New York
Krause KH, Dressel SH, Krause J et al (2003) The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci Biobehav Rev 27:605–613
PubMedCrossRefKuperman S, Perry PJ, Gaffney GR et al (2001) Bupropion vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry 13:129–134
PubMedCrossRefLandgraf D, McCarthy MJ, Welsh DK (2014) Circadian clock and stress interactions in the molecular biology of psychiatric disorders. Curr Psychiatry Rep 16:483
PubMedCrossRefLatimer K, Wilson P, Kemp J et al (2012) Disruptive behaviour disorders: a systematic review of environmental antenatal and early years risk factors. Child Care Health Dev 38:611–628
PubMedCrossRefLavialle M, Denis I, Guesnet P, Vancassel S (2010) Involvement of omega-3 fatty acids in emotional responses and hyperactive symptoms. J Nutr Biochem 21:899–905
PubMedCrossRefLeonard BE, McCartan D, White J, King DJ (2004) Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 19:151–180
PubMedCrossRefMarkowitz JS, Patrick KS (2001) Pharmacokinetic and pharmakodynamic drug interactions in the treatment of attention deficit hyperactivity disorder. Clin Pharmacokinet 40:753–772
PubMedCrossRefMartinez-Raga J, Knecht C, de Alvaro R (2015) Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder. Neuropsychiatr Dis Treat 11:1359–1370
PubMedPubMedCentralCrossRefMatthies SD, Philipsen A (2014) Common ground in Attention Deficit Hyperactivity Disorder (ADHD) and Borderline Personality Disorder (BPD)-review of recent findings. Borderline Personal Disord Emot Dysregul 1:3
PubMedPubMedCentralCrossRefMcCarthy S, Asherson P, Coghill D et al (2009) Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry 194:273–277
PubMedCrossRefMcCarthy S, Wilton L, Murray ML et al (2012) The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatr 12:78
PubMedPubMedCentralCrossRefMedori R, Ramos-Quiroga A, Casas M et al (2008) A randomized, placebo-controlled trial of three fixed dosages of prolonged release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 63:981–989
PubMedCrossRefMichelson D, Adler L, Spencer T et al (2003) Atomoxetin in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112–120
PubMedCrossRefMichielsen M, Comijs HC, Aartsen MJ et al (2015) The relationships between ADHD and social functioning and participation in older adults in a population-based study. J Atten Disord 19:368–379
PubMedCrossRefMick E, Faraone SV, Biederman J (2004) Age-dependent expression of attention deficit hyperactivity disorder symptoms. Psychiatr Clin North Am 27:215–224
PubMedCrossRefMongia M, Hechtman L (2012) Cognitive behavior therapy for adults with attention-deficit/hyperactivity disorder: a review of recent randomized controlled trials. Curr Psychiatry Rep 14:561–567
PubMedCrossRefMurray C, Johnston C (2006) Parenting in mothers with and without attention-deficit/hyperactivity disorder. J Abnorm Psychol 115:52–61
PubMedCrossRefNational Institute for Health and Clinical Excellence (NICE) (2009) Attention deficit hyperactivity disorder – diagnosis and management of ADHD in children, young people and adults, NICE clinical guideline, 72. The British Psychological Society and The Royal College of Psychiatrists, London
Nierenberg AA, Miyahara S, Sprencer T et al (2005) Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000STEP-BD participants. Biol Psychiatry 57:1467–1473
PubMedCrossRefNigg JT, Tannock R, Rohde LA (2010) What is to be the fate of ADHD subtypes? An introduction to the special section on research on the ADHD subtypes and implications for the DSM-V. J Clin Child Adolesc Psychol 39(6):723–725
PubMedCrossRefNutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, Morris KA, Santosh P, Sonuga-Barke E, Taylor E, Weiss M, Young S, British Association for Psychopharmacology (2007) Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 21(1):10–41
PubMedCrossRefOnnink AM, Zwiers MP, Hoogman M et al (2014) Brain alterations in adult ADHD: effects of gender, treatment and comorbid depression. Eur Neuropsychopharmacol 24:397–409
PubMedCrossRefPaloyelis Y, Mehta MA, Kuntsi J et al (2007) Functional MRI in ADHD: a systematic literature review. Expert Rev Neurother 7:1337–1356
PubMedPubMedCentralCrossRefPaslakis G, Schredl M, Alm B, Sobanski E (2013) Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Erwachsenen mit assoziierter Symptomatik und komorbiden psychiatrischen Erkrankungen: Diagnostik und medikamentöse Behandlung. Fortschr Neurol Psychiatr 81(8):444–451
PubMedCrossRefPaterson R, Douglas C, Hallmayer J et al (1999) A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry 33:494–502
PubMedCrossRefPérez de los Cobos J, Siñol N, Pérez V, Trujols J (2012) Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity and addiction. Br J Clin Pharmacol 77(2):337–356
CrossRefPhilipsen A (2012) Psychotherapy in adult attention deficit hyperactivity disorder: implications for treatment and research. Expert Rev Neurother 12(10):1217–1225
PubMedCrossRefPhilipsen A, Richter H, Peters J et al (2007) Efficacy of a structured group psychotherapy in adults with attention-deficit-hyperactivity disorder: results of a multicenter study. J Nerv Ment Dis 195(12):1013–1019
PubMedCrossRefPhilipsen A, Limberger MF, Lieb K et al (2008) Attention-deficit hyperactivity disorder as a potentially aggravating factor in borderline personality disorder. Br J Psychiatry 192(2):118–123
PubMedCrossRefPhilipsen A, Jans T, Graf E et al (2015) Effects of group psychotherapy, individual counseling, methylphenidate, and placebo in the treatment of adult attention deficit hyperactivity disorder. JAMA Psychiatry 72(12):1199–210
Pitts M, Mangle L, Asherson P (2015) Impairments, diagnosis and treatments associated with attention-deficit/hyperactivity disorder (ADHD) in UK adults: results from the lifetime impairment survey. Arch Psychiatr Nurs 29(1):56–63
PubMedCrossRefPolanczyk G, Caspi A, Houts R et al (2010) Implications of extending the ADHD age-of-onset criterion to age 12: results from a prospectively studied birth cohort. J Am Acad Child Adolesc Psychiatry 49(3):210–216
PubMedReimherr FW, Williams ED, Strong RE et al (2007) A double-blind crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 68:93–101
PubMedCrossRefRetz W, Stieglitz RD, Corbisiero S et al (2012) Emotional dysregulation in adult ADHD: what is the empirical evidence? Expert Rev Neurother 12(10):1241–1251
Retz W, Retz-Junginger P, Rösler M (2012, 2015) Integrierte Diagnose der ADHS im Erwachsenenalter – IDA. Medice, Iserlohn
Retz W, Retz-Junginger P, Römer K, Rösler M (2013) Standardised psychopathological rating scales for the diagnosis of ADHD in adults. Fortschr Neurol Psychiatr 81(7):381–389
PubMedCrossRefRivera HM, Christiansen KJ, Sullivan EL (2015) The role of maternal obesity in the risk of neuropsychiatric disorders. Front Neurosci 9:194
PubMedPubMedCentralCrossRefRösler M, Retz W, Retz-Junginger P et al (2004) Prevalence of attention deficit-/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci 254(6):365–371
PubMedCrossRefRösler M, Retz-Junginger P, Retz W, Stieglitz RD (2008) HASE – Homburger ADHS-Skalen für Erwachsene. Hogrefe, Göttingen
Rösler M, Fischer R, Ammer R et al (2009) A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 259:120–129
PubMedCrossRefRösler M, Retz W, Fischer R et al (2010) Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD. World J Biol Psychiatry 11:709–718
PubMedCrossRefRostain AL, Ramsay JR (2006) A combined treatment approach for adults with ADHD – results of an open study of 43 patients. J Atten Disord 10(2):150–159
PubMedCrossRefRubia K, Overmeyer S, Taylor E et al (1999) Functional frontalisation with age: mapping neurodevelopmental trajectories with fMRI. Neurosci Biobehav Rev 24:13–19
CrossRefRubia K, Alegria A, Brinson H (2014) Imaging the ADHD brain: disorder-specificity, medication effects and clinical translation. Expert Rev Neurother 14:519–538
PubMedCrossRefSafren SA (2006) Cognitive-behavioral approaches to ADHD treatment in adulthood. J Clin Psychiatry 67(Suppl 8):46–50. Review
PubMedSafren SA, Otto MW, Sprich S (2005a) Cognitive behavioural therapy of ADHD in medication-treated adults with continued symptoms. Behav Res Ther 43:831–842
PubMedCrossRefSafren SA, Perlman CA, Sprich S, Otto MW (2005b) Mastering your adult ADHD: a cognitive behavioural treatment program. Oxford University Press, Oxford/New York
CrossRefSafren SA, Sprich S, Mimiaga MJ et al (2010) Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA 304(8):875–880
PubMedPubMedCentralCrossRefSchatzberg AF, Kelsey DK, Williams DW (2007) Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68:582–587
PubMedCrossRefSchmidt S, Petermann F (2013) ADHS-Screening für Erwachsene (ADHS-E), 2. überarbeitete und erweiterte Auflage. Frankfurt Pearson Assessment, Frankfurt
Schredl M, Alm B, Sobanski E (2007) Sleep quality in adult patients with attention deficit hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 257(3):164–168
PubMedCrossRefSchütte V, Petermann F (2006) Soziale Beziehungen und Partnerschaft bei Erwachsenen mit ADHS – eine Phänomenbeschreibung anhand einer Fragebogenstudie. Verhaltenstherapie & Verhaltensmedizin 27:157–172
Schweitzer JB, Faber TL, Grafton ST et al (2000) Alterations in the functional anatomy of working memory in adult attention deficit hyperactivity disorder. Am J Psychiatry 157(2):278–280
PubMedCrossRefSeidman LJ (2006) Neuropsychological functioning in people with ADHD across the lifespan. Clin Psychol Rev 26:466–485
PubMedCrossRefSeidman LJ, Valera EM, Bush G (2004) Brain function and structure in adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 27:323–347
PubMedCrossRefSeixas M, Weiss M, Müller U (2011) Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J Psychopharmacol 24:753–765
Sergeant JA (2005) Modeling attention-deficit/hyperactivity disorder: a critical appraisal of the cognitive-energetic model. Biol Psychiatry 57:1248–1255
PubMedCrossRefSimon V, Czobor P, Bálint S, Mészáros A, Bitter I (2009) Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 194:204–211
PubMedCrossRefSinn N (2008) Nutritional and dietary influences on attention deficit hyperactivity disorder. Nutr Rev 66:558–568
PubMedCrossRefSobanski E, Alm B (2004) Aufmerksamkeitsdefizit/Hyperaktivitätsstörung (ADHS) bei Erwachsenen. Nervenarzt 75:697–715
PubMedCrossRefSobanski E, Alm B (2010) Aufmerksamkeitsdefizit-/Hyperaktivitätstörung des Erwachsenenalters (ADHS) und Persönlichkeitstörungen. Nervenheilkunde (1-2):31–34
Sobanski E, Alm B, Krumm B (2007a) Methylphenidatbehandlung bei erwachsenen Patienten mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS): Bedeutung von Störungssubtyp und psychiatrischer Komorbidität. Nervenarzt 78:328–337
PubMedCrossRefSobanski E, Brüggemann D, Alm B et al (2007b) Psychiatric comorbiditiy and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivitiy disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 257(7):371–377
PubMedCrossRefSobanski E, Brüggemann D, Alm B (2008a) Subtype specific differences in adults with attention-deficit/hyperactivity disorder (ADHD) with regard to ADHD-symptoms, psychiatric comorbidity and psychosocial adjustment. Eur Psychiatry 23:142–149
Sobanski E, Sabljic D, Alm B et al (2008b) Driving-related risks and impact of methylphenidate treatment on driving in adults with attention-deficit/hyperactivity disorder. J Neur Trans 115:347–356
Sobanski E, Schredl M, Kettler N, Alm B (2008c) Sleep in adults with attention-deficit hyperactivity disorder before and during treatment with methylphenidate: a controlled polysomnographic study. Sleep 31(3):375–381
Sobanski E, Schuhmacher-Stien M, Alm B (2009) Kognitive Verhaltenstherapie der ADHS des Erwachsenen. Medizinisch wissenschaftliche Verlagsgesellschaft, Berlin. Dtsch. Ausgabe des Originaltitels: Safren SA, Perlman CA, Sprich S, Otto MW (2005b) Mastering your adult ADHD: a cognitive behavioural treatment program. Oxford University Press, Oxford/New York
Sobanski E, Sabljic D, Alm B et al (2011) A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with ADHD. Pharmacopsychiatry 45:100–107
PubMedSobanski E, Sabljic D, Alm B et al (2012) Driving performance in adults with ADHD: results from a randomized, waiting list controlled trial with atomoxetine. Eur Psychiatry 28(6):379–385
PubMedCrossRefSobanski E, Paslakis G, Schredl M, Daffner S, Alm B (2013) Chapter 8. Managing ADHD in adults with common comorbidities. In: Surman CBH (Hrsg) ADHS in adults: a practical guide to evaluation and management, current clinical psychiatry. Springer, New York
Sobanski E, Leppämäki S, Bushe C et al (2015a) Patterns of long-term and short-term responses in adult patients with attention-deficit/hyperactivity disorder in a completer cohort of 12 weeks or more with atomoxetine. Eur Psychiatry (Accepted)
Sobanski E, Sirtl A, Alm B, Hennig O, Banaschewski T (2015a) Neuropsychological functioning and psychosocial outcome in adults with attention-deficit/hyperactivity disorder. Z Neuropsychol 26(1):17–26
CrossRefSokolova E, Hoogman M, Groot P et al (2015) Causal discovery in an adult ADHD data set suggests indirect link between DAT1 genetic variants and striatal brain activation during reward processing. Am J Med Genet B Neuropsychitr Genet
Sokunbi MO, Fung W, Sawlani V et al (2013) Resting state fMRI entropy probes complexity of brain activity in adults with ADHD. Psychiatry Res 214:341–348
PubMedCrossRefSolanto MV, Marks DJ, Wasserstein J et al (2010) Efficacy of meta-cognitive therapy for adult ADHD. Am J Psychiatry 167(8):958–968
PubMedPubMedCentralCrossRefSonuga-Barke EJS (2005) Causal models of ADHD: from common simple deficits to multiple developmental pathways. Biol Psychiatry 57:1231–1238
PubMedCrossRefSonuga-Barke EJ, Castellanos FX (2007) Spontaneous attentional fluctuations in impaired states and pathological conditions: a neurobiological hypothesis. Neurosci Biobehav Rev 31(7):977–986
PubMedCrossRefSpencer T, Wilens TE, Biederman SV et al (1995) A double-blind, cross-over comparison of methylphenidate and placebo in adults with childhood onset attention deficit hyperactivity disorder. Arch Gen Psychiatry 52:434–443
PubMedCrossRefSpencer T, Biederman J, Wilens T et al (1998) Effectivness and tolerability of tomoxetine in adults with attention-deficit hyperactivity disorder. Am J Psychiatry 155:693–695
PubMedCrossRefSpencer T, Biederman J, Wilens T et al (2005) A large double-blind, randomized trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 57:456–463
PubMedCrossRefSpencer TJ, Faraone SV, Michelson D et al (2006) Atomoxetine and adult attentiondeficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry 67:415–420
PubMedCrossRefSpencer T, Biederman J, Wilens T et al (2008) Attention-deficit/hyperactivity disorder-specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 69(11):1766–1775
PubMedCrossRefStrohbeck-Kühner P, Sobanski E, Skopp G et al (2006) ADHS und Fahreignung. Z Verkehrssicherheit 1:18–22
Swift KD, Sayal K, Hollis C (2013) ADHD and transitions to adult mental health services: a scoping review. Child Care Health Dev 40(6):775–786. Epub 25 Oct 2013. Review
PubMedCrossRefTaylor N, Fauset A, Val H (2010) Young adults with ADHD: an analysis of their service needs on transfer to adult services. Arch Dis Child 95:513–517
PubMedCrossRefThapar A, Cooper M (2016) Attention deficit hyperactivity disorder. Lancet 387(10024);1240–50
Thapar A, Rice F, Hay D, Boivin J et al (2009) Prenatal smoking might not cause attention-deficit/hyperactivity disorder: evidence from a novel design. Biol Psychiatry 66:722–727
PubMedPubMedCentralCrossRefTorres I, Gómez N, Colom F et al (2015) Bipolar disorder with comorbid attention-deficit and hyperactivity disorder. Main clinical features and clues for an accurate diagnosis. Acta Psychiatr Scand
Upadhyaya HP (2007) Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder. J Clin Psychiatry 68(Suppl 11):23–30
PubMedVaidya CJ, Austin G, Kirkorian G et al (1998) Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad Sci U S A 95:14494–14499
PubMedPubMedCentralCrossRefVan Ameringen M, Mancini C, Simpson W, Patterson B (2011) Adult attention deficit hyperactivity disorder in an anxiety disorders population. CNS Neurosci Ther 17(4):221–226
PubMedCrossRefVan der Meere J, Vreeling HJ, Segeant J (1992) A motor presetting study in hyperactive, learning disabled and control children. J Child Psychol Psychiatry 33:1347–1354
PubMedCrossRefvan Emmerik-van Oortmerssen K, van de Glind G, van den Brink W et al (2012) Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend 122(1-2):11–19
CrossRefVermeiren R (2003) Psychopathology and delinquency in adolescents: a descriptive and developmental perspective. Clin Psychol Rev 23(2):277–318
PubMedCrossRefVidal-Estrada R, Bosch-Munso R, Nogueira-Morais M et al (2012) Psychological treatment of attention deficit hyperactivity disorder in adults: a systematic review. Actas Esp Psiquiatr 40(3):147–154
PubMedWarnke A, Walitza S (2004) Methylphenidat in der Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS). In: Schulte-Markwort M, Warnke A (Hrsg) Methylphenidat. Thieme, Stuttgart
Weintraub D, Mavandadi S, Mamikonyan E et al (2010) Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 75:444–455
CrossRefWeltgesundheitsorganisation (WHO) (1994) Internationale Klassifikation psychischer Störungen ICD-10. Hans Huber, Bern
Wender PH, Reimherr FW (1990) Bupropion treatment of attention deficit hyperactivity disorder in adults. Am J Psychiatry 147:1018–1120
PubMedCrossRefWender PH, Reimherr FW, Wood DR et al (1985) A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type in adults. Am J Psychiatry 142:547–552
PubMedCrossRefWender PH, Wolf LE, Wasserstein J (2001) Adults with ADHD. an overview. Ann N Y Acad Sci 931:1–16
PubMedCrossRefWernicke JF, Kratochvil CJ (2002) Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 63:50–55
PubMedWeyandt LL, Oster DR, Marraccini ME et al (2014) Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants. Psychol Res Behav Manag 7:223–249
PubMedPubMedCentralCrossRefWilens TE, Biederman J, Spencer TJ et al (1999) A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 156:1931–1937
PubMedWilens TE, Spencer TJ, Biederman J et al (2001) A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158:282–288
PubMedCrossRefWilens TE, Faraone SV, Biederman J et al (2003) Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111:179–185
PubMedCrossRefWilens TE, Hammerness PG, Biederman J et al (2005a) Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 66:253–259
PubMedCrossRefWilens TE, Haight BR, Horrigan JP et al (2005b) Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled trial. Biol Psychiatry 57:793–801
PubMedCrossRefWilens TE, Adler LA, Weiss MD et al (2008) Atomoxetine ADHD/SUD study group. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 96:145–154
PubMedCrossRefWillcutt EG, Nigg JT, Pennington BF et al (2012) Validity of DSM-IV attention deficit/hyperactivity disorder symptom dimensions and subtypes. J Abnorm Psychol 121(4):991–1010
PubMedPubMedCentralCrossRefWouldes T, LaGasse L, Sheridan J, Sesier B (2004) Maternal methamphetamine use during pregnancy and child outcome: what do we know? NZ Med J 117:U1180
Young S, Thome J (2011) ADHD and offenders. World J Biol Psychiatry 12(Suppl 1):124–128
PubMedCrossRefZametkin AJ, Nordahl TH, Gross M (1990) Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med 323:1361–1366
PubMedCrossRefZulauf CA, Sprich SE, Safren SA, Wilens TE (2014) The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders. Curr Psychiatry Rep 16(3):436
PubMedPubMedCentralCrossRefZylowksa L, Ackerman DL, Yang MH et al (2008) Mindfulness meditation training in adults and adolescents with ADHD: a feasibility study. J Atten Disord 11(6):737–746